Targeting NAD

ADP-ribosyl Cyclase 1 / antagonists & inhibitors Acrylamides / pharmacology Adenosine / metabolism Adenosine Diphosphate Ribose / metabolism Antibodies, Monoclonal / pharmacology Antibodies, Monoclonal, Humanized / pharmacology Antineoplastic Agents, Immunological / pharmacology Antineoplastic Combined Chemotherapy Protocols / pharmacology Cell Line, Tumor Cytokines / antagonists & inhibitors Drug Synergism Humans Membrane Glycoproteins / antagonists & inhibitors Multiple Myeloma / drug therapy NAD / antagonists & inhibitors Niacinamide / metabolism Nicotinamide Phosphoribosyltransferase / antagonists & inhibitors Piperidines / pharmacology T-Lymphocytes, Cytotoxic / drug effects T-Lymphocytes, Regulatory / drug effects Tumor Escape / drug effects Warburg Effect, Oncologic / drug effects
NAD(+) adenosine anti-CD38 therapy cancer metabolism daratumumab immunosuppression immunotherapy isatuximab multiple myeloma

Journal

Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956

Informations de publication

Date de publication:
01 2020
Historique:
received: 01 10 2019
revised: 07 11 2019
accepted: 17 11 2019
entrez: 19 1 2020
pubmed: 19 1 2020
medline: 16 6 2021
Statut: ppublish

Résumé

Antibodies targeting CD38, a NAD

Identifiants

DOI: 10.1016/j.trecan.2019.11.005 PMID: 31952784
pubmed: 31952784
pii: S2405-8033(19)30239-0
doi: 10.1016/j.trecan.2019.11.005
pii:
doi:

Substances chimiques

Acrylamides 0
Antibodies, Monoclonal 0
Antibodies, Monoclonal, Humanized 0
Antineoplastic Agents, Immunological 0
Cytokines 0
Membrane Glycoproteins 0
N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide 0
Piperidines 0
NAD 0U46U6E8UK
Adenosine Diphosphate Ribose 20762-30-5
Niacinamide 25X51I8RD4
daratumumab 4Z63YK6E0E
Nicotinamide Phosphoribosyltransferase EC 2.4.2.12
nicotinamide phosphoribosyltransferase, human EC 2.4.2.12
CD38 protein, human EC 3.2.2.5
ADP-ribosyl Cyclase 1 EC 3.2.2.6
Adenosine K72T3FS567
isatuximab R30772KCU0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9-12

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Barry E Kennedy (BE)

Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 1X5, Canada.

Maryanne Sadek (M)

Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 1X5, Canada.

Manal O Elnenaei (MO)

Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority (NSHA), Halifax, NS and Canada Department of Pathology, Dalhousie University, Halifax, NS B3H 1V8, Canada.

Anthony Reiman (A)

Department of Oncology, Saint John Regional Hospital, Dalhousie University and University of New Brunswick, Saint John, NB E2L 4L2, Canada.

Shashi A Gujar (SA)

Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 1X5, Canada; Department of Microbiology and Immunology, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 1X5, Canada; Department of Biology, Faculty of Science, Dalhousie University, Halifax, NS B3H 1X5, Canada; Beatrice Hunter Cancer Research Institute, Halifax, NS B3H 1X5, Canada. Electronic address: shashi.gujar@dal.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Glycoprotéines membranaires › Antigènes CD38 › Targeting NAD
questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Acides acycliques › Acrylates › Acrylamides › Targeting NAD
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Ribonucléosides › Adénosine › Targeting NAD
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Ribonucléotides › Nucléoside diphosphate ose › Adénosine diphosphate ose › Adénosine diphosphate ribose › Targeting NAD
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Targeting NAD
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Targeting NAD
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Targeting NAD
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Targeting NAD
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Targeting NAD
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Targeting NAD
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Interactions médicamenteuses › Synergie des médicaments › Targeting NAD
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Targeting NAD
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Glycoprotéines membranaires › Targeting NAD
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Myélome multiple › Targeting NAD
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Ribonucléotides › Nucléotides adényliques › NAD › Targeting NAD
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Acides nicotiniques › Nicotinamide › Targeting NAD
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Glycosyltransferase › Pentosyltransferases › Nicotinamide phosphoribosyltransferase › Targeting NAD
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipéridines › Targeting NAD
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Lymphocytes T cytotoxiques › Targeting NAD
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Lymphocytes T régulateurs › Targeting NAD
questionsmedicales.fr › Phénomènes du système immunitaire › Échappement de la tumeur à la surveillance immunitaire › Targeting NAD
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Respiration cellulaire › Effet Warburg en oncologie › Targeting NAD